Status of and Future Recommendations for Country-of-Origin Research

This research investigates whether country-of-origin (COO) cues have an effect on consumer purchase intentions, based on a review of prior literature published in the EBSCO and Summon databases. The findings of these articles show that COO cues do not, on their own, have an effect on consumer purchase intentions; but do have some effect on consumer attitudes/feelings toward the product. Future research has much to offer in terms of identifying whether COO cues have an effect on consumers’ purchase intentions for specific products, or specific types of products

Summer Cover Crop Mix Trial

Many farmers have realized the multitude of benefits cover crops provide in terms of soil health and fertility. Most farmers, however, plant cover crops in the fall to protect their soils from erosion through the winter into spring while they do not have a crop planted. Summer cover cropping may be another option for growers interested in building soil health. Summer cover crops could be planted throughout the season and offer a wide range of species to select from so benefits are maximized. Another benefit to growing cover crops during the summer is increased whole plant above and belowground biomass. Maximizing biomass can help improve soil quality far quicker than cover crops grown during fall months. Although some of the investigated crops are planted in the northeast as forage crops, little is known about the potential for combining multiple species with the goal of maximizing soil health benefits. In 2014, the University of Vermont Extension conducted a summer cover crop mix trial. This is the first trial evaluating summer cover crop species mixes in the northeast. The trial was established at the Borderview Research Farm in Alburgh, Vermont

Winter Barley Variety Trial

With the revival of the small grains industry in the Northeast and the strength of the localvore movement, craft breweries and distilleries have expressed an interest in sourcing local barley for malting. Malting barley must meet specific quality characteristics such as low protein content and high germination. Many farmers are also interested in barley as a concentrated, high-energy feed source for livestock. Depending on the variety, barley can be planted in either the spring or fall, and both two- and six-row barley can be used for malting and livestock feed. Winter barley has not been traditionally grown in the Northeast due to severe winterkill. However, newly developed varieties and a changing climate have encouraged our team to investigate this crop for the area. In 2013-2014, UVM Extension’s Northwest Crops and Soils Program conducted a winter barley trial to evaluate the yield and quality of malting and feed barley varieties

Heirloom Winter Wheat Variety Trial

Many consumers are interested in heirloom wheat for flavor, perceived health benefits or its history, while many farmers are interested in heirloom wheat because it may have superior genetics better adapted to the challenging growing conditions in the Northeast. Production of heirloom wheat may also provide a farmer with a value added market with increased returns. This variety trial was established to determine heirloom winter wheat varieties that are suitable for production in Vermont’s growing conditions. This was the third year that this trial was conducted in Vermont

Heirloom Spring Wheat Seeding Rate Trial

University of Vermont Extension began its heirloom spring wheat project in 2007 to determine whether heirloom varieties developed before 1950 could thrive in Vermont’s climate. Many consumers are interested in heirloom wheat as they feel it has better flavor, while many farmers are also interested in heirloom wheat varieties as they may have superior genetics that are better adapted to the challenging growing conditions in the Northeast. Several producers have asked questions about the best agronomic practices for cultivating heirloom wheat. It is unclear if heirloom wheat will require lower seeding rates as compared to modern day varieties. Seeding rates can influence weed populations as well as overall yield and quality. The purpose of this trial was to determine optimum seeding rates for heirloom spring wheat in Vermont

Spring Wheat Crosses Trial

On-farm wheat breeding began in Vermont, in cooperation with UVM Extension, in 2007 with a USDA SARE grant to build farmer knowledge in plant breeding. The goal of this on-farm breeding trial is to develop spring wheat varieties that are suited for organic management in Vermont soils and climatic conditions. Most commercially available varieties are developed in regions with climates, soils and management techniques that are very different from our own. In addition, those varieties are genetically homogenous and inbred for uniformity. This has often led to rapid breakdown of genetic resistance to local diseases. To address this situation, farmers in Vermont have been gaining the technical skills needed to develop their own varieties by making wheat crosses and selections under organic management

ASASSN-18am/SN 2018gk : An overluminous Type IIb supernova from a massive progenitor

ASASSN-18am/SN 2018gk is a newly discovered member of the rare group of luminous, hydrogen-rich supernovae (SNe) with a peak absolute magnitude of $M_V \approx -20$ mag that is in between normal core-collapse SNe and superluminous SNe. These SNe show no prominent spectroscopic signatures of ejecta interacting with circumstellar material (CSM), and their powering mechanism is debated. ASASSN-18am declines extremely rapidly for a Type II SN, with a photospheric-phase decline rate of $\sim6.0~\rm mag~(100 d)^{-1}$. Owing to the weakening of HI and the appearance of HeI in its later phases, ASASSN-18am is spectroscopically a Type IIb SN with a partially stripped envelope. However, its photometric and spectroscopic evolution show significant differences from typical SNe IIb. Using a radiative diffusion model, we find that the light curve requires a high synthesised $\rm ^{56}Ni$ mass $M_{\rm Ni} \sim0.4~M_\odot$ and ejecta with high kinetic energy $E_{\rm kin} = (7-10) \times10^{51}$ erg. Introducing a magnetar central engine still requires $M_{\rm Ni} \sim0.3~M_\odot$ and $E_{\rm kin}= 3\times10^{51}$ erg. The high $\rm ^{56}Ni$ mass is consistent with strong iron-group nebular lines in its spectra, which are also similar to several SNe Ic-BL with high $\rm ^{56}Ni$ yields. The earliest spectrum shows "flash ionisation" features, from which we estimate a mass-loss rate of $\dot{M}\approx 2\times10^{-4}~\rm M_\odot~yr^{-1}$. This wind density is too low to power the luminous light curve by ejecta-CSM interaction. We measure expansion velocities as high as $17,000$ km/s for $H_\alpha$, which is remarkably high compared to other SNe II. We estimate an oxygen core mass of $1.8-3.4$ $M_\odot$ using the [OI] luminosity measured from a nebular-phase spectrum, implying a progenitor with a zero-age main sequence mass of $19-26$ $M_\odot$

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV

Objectives The aim of the study was to describe agreement between the QRISK2, Framingham and Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) cardiovascular disease (CVD) risk calculators in a large UK study of people living with HIV (PLWH). Methods PLWH enrolled in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study without a prior CVD event were included in this study. QRISK2, Framingham CVD and the full and reduced D:A:D CVD scores were calculated; participants were stratified into ‘low’ ( 20%) categories for each. Agreement between scores was assessed using weighted kappas and Bland–Altman plots. Results The 730 included participants were predominantly male (636; 87.1%) and of white ethnicity (645; 88.5%), with a median age of 53 [interquartile range (IQR) 49–59] years. The median calculated 10‐year CVD risk was 11.9% (IQR 6.8–18.4%), 8.9% (IQR 4.6–15.0%), 8.5% (IQR 4.8–14.6%) and 6.9% (IQR 4.1–11.1%) when using the Framingham, QRISK2, and full and reduced D:A:D scores, respectively. Agreement between the different scores was generally moderate, with the highest level of agreement being between the Framingham and QRISK2 scores (weighted kappa = 0.65) but with most other kappa coefficients in the 0.50–0.60 range. Conclusions Estimates of predicted 10‐year CVD risk obtained with commonly used CVD risk prediction tools demonstrate, in general, only moderate agreement among PLWH in the UK. While further validation with clinical endpoints is required, our findings suggest that care should be taken when interpreting any score alone